An Open-label, Dose-Escalation, Multiple-Dose Phase 1 Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets in Caucasian Healthy Subjects After Oral Administrations
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Deuremidevir hydrobromide (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Shanghai Vinnerna Biosciences
Most Recent Events
- 07 Feb 2023 Status changed from not yet recruiting to withdrawn prior to enrolment (Development strategy adjustment)
- 06 May 2022 New trial record